Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BCTXNASDAQ:LIPONASDAQ:NERVNASDAQ:ONCR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCTXBriaCell Therapeutics$3.12-11.6%$3.78$2.81▼$29.40$11.57M1.3549,972 shs124,884 shsLIPOLipella Pharmaceuticals$2.56-5.6%$2.61$1.97▼$12.00$11.43M0.44722,899 shs21,329 shsNERVMinerva Neurosciences$1.83+2.2%$1.61$1.15▼$3.69$12.76M-0.3724,215 shs6,750 shsONCROncorus$0.13$0.07$0.01▼$0.47$3.29M3.61.33 million shs135,947 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCTXBriaCell Therapeutics-11.61%-9.30%+4.00%-18.75%-84.12%LIPOLipella Pharmaceuticals-5.57%-14.41%+7.07%+19.02%-50.79%NERVMinerva Neurosciences+2.24%-0.22%+18.63%+18.51%-43.85%ONCROncorus0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBCTXBriaCell Therapeutics1.6878 of 5 stars3.52.00.00.01.80.00.6LIPOLipella Pharmaceuticals2.2395 of 5 stars0.05.00.00.02.73.30.6NERVMinerva Neurosciences3.3986 of 5 stars3.03.00.04.62.20.00.0ONCROncorusN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCTXBriaCell Therapeutics 3.00Buy$32.00925.64% UpsideLIPOLipella Pharmaceuticals 0.00N/AN/AN/ANERVMinerva Neurosciences 2.00Hold$5.00173.97% UpsideONCROncorus 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ONCR, BCTX, LIPO, and NERV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/22/2025BCTXBriaCell TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$32.00 ➝ $32.00(Data available from 6/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCTXBriaCell TherapeuticsN/AN/AN/AN/A($2.20) per shareN/ALIPOLipella Pharmaceuticals$536.36K21.31N/AN/A$4.33 per share0.59NERVMinerva NeurosciencesN/AN/AN/AN/A($4.07) per shareN/AONCROncorusN/AN/AN/AN/A$2.33 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCTXBriaCell Therapeutics-$4.79M-$5.03N/AN/AN/AN/AN/A-191.19%N/ALIPOLipella Pharmaceuticals-$4.62M-$4.08N/A∞N/A-882.82%-192.33%-154.24%N/ANERVMinerva Neurosciences-$30M$0.82N/AN/AN/AN/AN/A-6.74%8/5/2025 (Estimated)ONCROncorus-$77.42M-$3.49N/A∞N/AN/AN/AN/AN/ALatest ONCR, BCTX, LIPO, and NERV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025LIPOLipella PharmaceuticalsN/A-$0.64N/A-$0.64N/A$0.13 million5/13/2025Q1 2025NERVMinerva Neurosciences-$1.07-$0.50+$0.57-$0.50N/AN/A3/27/2025Q4 2024LIPOLipella Pharmaceuticals-$2.43-$1.19+$1.24-$1.19N/A$0.17 million3/17/2025Q2 2025BCTXBriaCell Therapeutics-$1.94-$2.33-$0.39-$2.33N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBCTXBriaCell TherapeuticsN/AN/AN/AN/AN/ALIPOLipella PharmaceuticalsN/AN/AN/AN/AN/ANERVMinerva NeurosciencesN/AN/AN/AN/AN/AONCROncorusN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCTXBriaCell TherapeuticsN/A1.651.65LIPOLipella PharmaceuticalsN/A2.972.97NERVMinerva NeurosciencesN/A6.236.23ONCROncorusN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCTXBriaCell Therapeutics15.42%LIPOLipella Pharmaceuticals74.31%NERVMinerva Neurosciences34.56%ONCROncorus20.07%Insider OwnershipCompanyInsider OwnershipBCTXBriaCell Therapeutics5.73%LIPOLipella Pharmaceuticals32.11%NERVMinerva Neurosciences8.60%ONCROncorus17.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCTXBriaCell Therapeutics83.71 million3.50 millionOptionableLIPOLipella Pharmaceuticals44.47 million821,000Not OptionableNERVMinerva Neurosciences96.99 million6.39 millionNot OptionableONCROncorus6426.09 million21.63 millionOptionableONCR, BCTX, LIPO, and NERV HeadlinesRecent News About These CompaniesRFL Rafael Holdings, Inc.August 1, 2024 | seekingalpha.comOncorus Inc rdinary Shares Stock (OTC:ONCR) Dividends: History, Yield and DatesFebruary 26, 2024 | benzinga.comOncorus, Inc. (ONCR) stock price, news, quote & history – Yahoo FinanceDecember 29, 2023 | uk.finance.yahoo.comComera Life Sciences Holdings IncDecember 18, 2023 | investing.comOncorus Inc Ordinary SharesOctober 28, 2023 | morningstar.comONCR Historical DataOctober 16, 2023 | investing.comOncorus Inc. (ONCR) receives a Buy rating from Maxim GroupJune 21, 2023 | knoxdaily.comTaking a look at what insiders are doing to gauge the Oncorus Inc. (ONCR)’s directionJune 16, 2023 | knoxdaily.comWhat's Going On With Oncorus (ONCR) Stock Friday?June 16, 2023 | msn.comMaxim Group gives a Buy recommendation for Oncorus Inc. (ONCR)June 15, 2023 | knoxdaily.comONCR price target predicted to rise nearly $1.50 in 12 monthsJune 9, 2023 | knoxdaily.comOncorus could file for bankruptcy as most employees laid off; down 43%June 2, 2023 | msn.comDays-to-cover ratio for ONCR declines to 2.51 due to decline in short interestJune 1, 2023 | knoxdaily.comOncorus Announces Workforce Reduction PlanJune 1, 2023 | finance.yahoo.comOncorus, Inc.: Oncorus Reports First Quarter 2023 Financial Results and Provides Business UpdatesMay 23, 2023 | finanznachrichten.deRecap: Oncorus Q1 EarningsMay 22, 2023 | msn.comOncorus Reports First Quarter 2023 Financial Results and Provides Business UpdatesMay 22, 2023 | finance.yahoo.comOncorus, Inc.: Oncorus Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business UpdatesMarch 24, 2023 | finanznachrichten.deOncorus Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business UpdatesMarch 24, 2023 | finance.yahoo.comFor some biotechs moving on from SVB, not all traditional banks are an optionMarch 15, 2023 | bizjournals.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeONCR, BCTX, LIPO, and NERV Company DescriptionsBriaCell Therapeutics NASDAQ:BCTX$3.12 -0.41 (-11.61%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$3.15 +0.03 (+0.96%) As of 06/13/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.Lipella Pharmaceuticals NASDAQ:LIPO$2.56 -0.15 (-5.57%) Closing price 06/13/2025 03:58 PM EasternExtended Trading$2.56 +0.00 (+0.04%) As of 06/13/2025 05:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lipella Pharmaceuticals Inc., a biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. The company develops LP-10, a formulation of tacrolimus that has completed Phase 2a clinical trial for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; and LP-410, an oral liposomal formulation of tacrolimus for the treatment of oral graft-versus-host disease (GVHD). Lipella Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania.Minerva Neurosciences NASDAQ:NERV$1.77 -0.02 (-1.06%) As of 06/13/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.Oncorus NASDAQ:ONCROncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company develops ONCR-021 for the treatment of non-small cell lung cancer, renal cell carcinoma, melanoma, and anaplastic thyroid cancer; and ONCR-788 for the treatment of small cell lung cancer, neuroendocrine prostate, and other neuroendocrine cancers. Oncorus, Inc. was incorporated in 2015 and is headquartered in Andover, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 Alphabet Enters a Bull Market: Is It Time to Buy? Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
